



### **DISCLAIMER**

This presentation is not a prospectus nor an offer for securities in any jurisdiction nor a securities recommendation. The information in this presentation is an overview and is based on publicly available information and internally developed data and does not contain all information necessary for investment decisions. In making investment decisions in connection with any acquisition of securities, investors should rely upon their own examination of the assets and consult their own legal, business and/or financial advisors and should not be relied on in connection with a decision to purchase or sell any securities.

The information contained in this presentation has been prepared in good faith by HRL Holdings Limited ("HRL") however, no representation nor warranty expressed or implied is made as to the accuracy, correctness, completeness or adequacy of any statements, estimates, opinions or other information contained in this presentation.

Investment in HRL is subject to investment risk, including possible loss of income and capital invested. The occurrence of events in the future are subject to risks, uncertainties and other factors that may impact HRL's actual results, performance or achievements to differ from those referred to in this presentation. Neither HRL, nor any other member company of the HRL Group, nor any officer or employee guarantees any particular rate of return or performance, nor do they guarantee the repayment of capital. Further, they do not give any assurance or guarantee that the occurrence of the events referred to in this presentation will actually occur as contemplated.

The presentation may contain forward-looking statements regarding the potential of the Company's revenues, projects, interests and the development potential of the Company's business. Any statement describing a goal, expectation, intention or belief of the Company is a forward-looking statement and should be considered an at-risk statement. Given these risks, readers are cautioned not to rely on forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements due to many important factors, risks and uncertainties including, without limitation, risk associated with product sales, development and manufacture, risks inherent in the business, future capital needs, general economic uncertainty and other risks detailed from time to time in the Company's announcements to the ASX.





## WHO WE ARE











#### WHAT WE DO







# BRANCH NETWORK



#### LABORATORY SERVICES











### HRL WELCOMES NEW CHAIRMAN



Greg previously worked at ALS Limited (ASX:ALQ) for 36 years and was the MD/CEO for twelve years until 2017. Under Greg's leadership, the Brisbane-based company, which was formerly known as Campbell Brothers, entered the ASX100 as it grew from a market capitalisation of \$381 million in 2005 to \$3.4 billion today.

Greg holds a BSc (Chem) with Post Graduate First Class Honours



## WHO BUYS OUR TESTING















# WHY THEY BUY IT









# **MEGATRENDS**



Rising Asian demand for clean and green Australasian food



Rising consumer demand for authentic and traceable food and beverages



Private sector focus on environmental stewardship and social licence



Increasing regulation and the need for demonstrable compliance



Focus on personal / worker health and well-being



# **OUR MAJOR SHAREHOLDERS**

## **Share holder composition:**

Board and management	~21%
Institutional	~59%
Other	~20%

#### **Substantial holders >5%**

Viburnum Funds	19%		
Perennial Value	14%		
Entities associated with Terry Cooney	7%		



# FINANCIAL RESULT OVERVIEW

	DEC 2018 \$000's	DEC 2017 \$000's	INCREASE \$000's
Revenues	14,103	10,979	3,124
Underlying EBITDA <sup>1</sup>	711	1,430	(719)
Operating cash flows generated <sup>2</sup>	(58)	1,042	(1,100)
Working capital	524	3,229	(2,705)
Net cash/(borrowings)	2,823	3,144	(321)
Statutory profit/(loss) after tax <sup>3</sup>	(4,226)	(156)	(4,070)

Underlying EBITDA and profit reflects statutory profit as adjusted to reflect the Directors' assessment of the result for the
ongoing business activities of the Group, in accordance with AICD/Finsia principles of recording underlying profit.
Underlying profit has not been audited. Refer to Appendix A for further details of non-underlying items.

- 2. Excludes cash outflows associated with acquisition & JV costs.
- 3. Statutory loss includes a number of non-operating amortizations detailed in Appendix A




# **SEGMENT PERFORMANCE – H1 FY2019**

	TRADING DIVISIONS			CORPORATE	CONSOLIDATED		
	HAZMAT	GEOTECH	FOOD/ENVIRO LABORATORY	SOFTWARE	TOTAL		
	\$000's	\$000's	\$000's	\$000's	\$000's	\$000'S	\$000's
Revenues	3,741	4,045	6,051	242	14,079	-	14,079
Underlying EBITDA (\$)	(25)	96	1,556	86	1,713	(1,002)	711
Underlying EBITDA (%)	(1%)	2%	26%	35%	12%	-	5%
Operating depreciation and amortisation	(210)	(100)	(675)	(14)	(1,000)	(6)	(1,005)
Net interest expense	(18)	(8)	-	-	(26)	16	10
Underlying profit before tax	(253)	(12)	881	72	688	(993)	(305)
Operating income tax	71	3	(247)	(20)	(193)	358	165
Underlying profit after tax	(182)	(9)	634	52	495	(635)	(140)
Non-operating adjustments							
JV incorporation related expenses	-	-	(22)	-	(22)	-	(22)
Earn-out expenses/adjustments	-	-	(2,722)	188	(2,534)	-	(2,534)
Amortisation of intangible assets arising from acquisitions	(77)	(512)	(892)	(601)	(2,082)	-	(2,082)
Share based payments	-	-	-	-	-	(31)	(31)
Share of loss - equity accounted investment	-	-	(10)	-	(10)	-	(10)
Non-operating income tax	22	141	256	165	584	9	593
Statutory profit after income tax	(237)	(380)	(2,756)	(196)	(3,569)	(657)	(4,226)





## **OUR FY2019 DELIVERABLES**





## **OPERATIONAL HIGHLIGHTS**

Analytica, earnout upper target exceeded. Reduces acquisition multiple to 5x.1

Precise laboratories to transfer across to Analytica and be fully integrated



Property costs reduced through consolidation of Nerang and Yatala sites in December



New laboratory tests launched including:

**NMR** for honey

**PFAS** in water

Beta casein genomics

CAIQTEST achieved full accreditation

FOODLAB has new facility and is currently recruiting for GM



# ANALYTICA SALES GROWTH DECEMBER 2018 VS DECEMBER 2017

	Environmental	+55%
	Dairy	+29%
118	Honey	+29%



## December 2018 vs PCP

**Revenue** up 21% to \$6.051m **EBITDA** \$1.556m vs \$1.577m proforma basis





## **OUTLOOK FOR FY2019**

Leverage Analytica intellectual property and know-how to enter new service lines in both Australia and New Zealand

Utilise new equipment, technology and software platforms to improve efficiencies and margins Focused business development plans to target new customers and protect the existing customer base

Continued focus on crossselling opportunities across all business units Geographical expansion into new markets when justified

Support CAIQTest (Pacific) with testing for food exports to China

Use the OCTFOLIO software platform to target new customers and provide enhanced service offerings to existing customers of the other business units

# **CONTACTS AND MORE INFORMATION**

Steven Dabelstein CEO

0405 770 166 steven.dabelstein@hrlholdings.com

www.hrlholdings.com



**Michael Harvey CFO** 

0409 334 366 michael.harvey@hrlholdings.com

www.hrlholdings.com



# APPENDIX A DETAILS ON NON-OPERATING PROFIT ADJUSTMENTS

ADJUSTMENT	DESCRIPTION
Acquisition related expenses	Acquisition related expenses relate to third party supplier costs connected to the establishment of Food Lab Pacific Limited joint venture.
Amortisation of intangible assets arising from acquisitions	The excess purchase price over the value of the tangible assets acquired during the acquisitions of Analytica, AAC Environmental, RJL & Associates, Morrison Geotechnic and OCTFOLIO has been allocated against specific identifiable intangible assets. These intangible assets are being amortised over a 2 – 5 year period.
Earn-out expenses/adjustments	The vendors of Analytica and Morrison Geotechnic have the opportunity to receive an earn-out payment if certain profit targets are met. Payment of the earn-out consideration is contingent on ongoing service of certain key staff, with the earn-out reduced proportionally if employment is terminated prior to the minimum service period.
	Analytica  Analytica exceeded the maximum EBITDA target for the 12 months ended 30 November 2018, resulting in an earn-out of NZ\$11,000,000. As at 31 December 2018, the vendors had performed 13 months of the 24-month service period (54.17%). Accordingly, an amount of NZ\$5,958,333 (AUD \$5,664,353) has been recognised as a provision in the balance sheet. The earnout expense attributable to this period of \$2,721,738 has been recognised in the income statement.
	OCTFOLIO OCTFOLIO is not expected to meet the minimum profit target to achieve the second stage earn-out payment and consequently the previously recognised provision of \$187,500 has been reversed in profit and loss.
Equity accounted share of loss	HRL has a 26% interest in CAIQTest (Pacific) Limited, a New Zealand based laboratory, providing pre-shipment testing services for clients exporting goods from Australasia to China.
	During the period CAIQTest (Pacific) Limited focused primarily on achieving the necessary accreditations with both the New Zealand and Chinese authorities. Consequently the reported results are not reflective of the underlying trading results of CAIQTest (Pacific) Limited.
Share based payments	In August 2016 HRL introduced a long term incentive plan for key management. The plan will focus on long term shareholder wealth creation and retention of key personnel. The value of these performance shares is being recognized as an expense in the income statement over the 3 year vesting period.